Navigation Links
Tetraphase Pharmaceuticals Completes Series B Financing to Support the Advancement of Novel Antibiotic Drug Candidates
Date:10/6/2009

WATERTOWN, Mass., Oct. 6 /PRNewswire/ -- Tetraphase Pharmaceuticals Inc. announced today that it has closed the first tranche of its $25 million Series B financing to support the advancement of several novel and potent antibiotic drug candidates. This Series B Financing and first tranche of $10 million was funded by existing investors -- Mediphase Venture Partners, CMEA Ventures, Fidelity Biosciences, Flagship Ventures and Skyline Ventures.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090910/NE72856LOGO )

Tetraphase Pharmaceuticals was established in August 2006 to advance and commercialize the ground-breaking synthetic chemistry platform developed by internationally recognized chemist, Dr. Andrew Myers of Harvard University. This proprietary platform overcomes a key barrier to discovering unprecedented classes of antibiotics and other drugs by enabling for the first time their total synthesis from basic building blocks. The initial focus of the company is on the discovery of novel antibiotics to treat drug-resistant infections.

"This is an exciting time for Tetraphase, as we move our lead compound into the clinic and advance our pipeline of novel and potent antibiotic drug candidates," said Guy Macdonald, President and Chief Executive Officer.

About Tetraphase Pharmaceuticals Inc.

Tetraphase Pharmaceuticals is capitalizing on breakthrough synthetic chemistry technology for drug discovery and development based on a process developed by world leading organic chemist Dr. Andrew Myers of Harvard University. This enabling advance in chemistry provides the company with a broad-range of commercial opportunities across a number of significant disease categories.

SOURCE Tetraphase Pharmaceuticals Inc.


'/>"/>
SOURCE Tetraphase Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Merz Pharmaceuticals Announces Phase III Data for NT 201 in Post-stroke Upper Limb Spasticity
2. Access Pharmaceuticals Signs eMarketing Agreement With iMedicor For MuGard(TM)
3. Conatus Pharmaceuticals to Present at the Montgomery Healthcare Conference
4. Bausch & Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux
5. ISTA Pharmaceuticals Announces Conference Call and Webcast of Third Quarter 2009 Financial Results
6. Alexza Pharmaceuticals to Present at the Fourth Annual JMP Securities Healthcare Focus Conference
7. Biostar Pharmaceuticals, Inc. Receives Patent for Aoxing Ganbao
8. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
9. Merriman Curhan Ford Acted as Financial Advisor to TorreyPines Therapeutics, Inc. in the Completed Merger With Raptor Pharmaceuticals Corp.
10. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
11. Fovea Pharmaceuticals to be Acquired by sanofi-aventis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... March 28, 2017  CASI Pharmaceuticals, Inc. (Nasdaq: ... addressing cancer and other unmet medical needs, announced ... for Cancer Research annual meeting.  The first poster ... "Evaluation of ENMD-2076 in Combination with Anti-PD1 ... poster to be presented on April 4 is ...
(Date:3/28/2017)... , March 28, 2017 Elysium ... with Cambridge academic ...   The Milner Therapeutics Institute today announces Elysium ... Health has committed significant investment for collaborative projects with academic ... four years. This is the first major research investment outside ...
(Date:3/27/2017)... -- A recent study at Shriners Hospitals for Children – ... country dedicated to the treatment of pediatric burns and ... Surfacide Helios ® UV-C Disinfection System is ... not killed by the EVS (manual) cleaning process alone." ... Association,s 49th Annual Meeting in Boston ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... The Radiology Business Management ... begun to serve as its new executive director. Mr. Still was selected through a ... , “Bob, as he is known to our members, has been a part ...
(Date:3/28/2017)... Wethersfield, Conn. (PRWEB) , ... March 28, 2017 ... ... company based in Wethersfield, Conn., has relocated its corporate headquarters to a new, ... and clients. , In October 2016, Qualidigm purchased a distressed office building ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... corrosive ions found in power plant water and steam. , Chlorides and sulfates ... and boilers, leading to extensive maintenance and unplanned shutdowns. Monitoring these ions at ...
(Date:3/28/2017)... ... March 28, 2017 , ... Columbus OH. Dr. Justin Harper, Founder of ... medical professionals in the country to sit on the 2017 National Advisory Board for ... 2 years Dr. Harper helped propel the clinic from a small start-up to number ...
(Date:3/28/2017)... Santa Monica, CA (PRWEB) , ... March 28, ... ... expert, Dr. Carson Liu of SkyLex Advanced Surgical, Inc. is thrilled to offer ... newest gastric balloon procedure, and this procedure adds to SkyLex Advanced Surgical’s ...
Breaking Medicine News(10 mins):